KALA Bio的短期利息上升,CEO出售股票,但主要投资者买入股票,尽管Q3亏损。 KALA Bio's short interest rose, CEO sold shares, but major investor bought in, despite Q3 losses.

KALA Bio是一家开展眼病治疗的公司,在1月短期利息上升了19.1%,共计25 600股。 KALA Bio, a company developing treatments for eye diseases, saw a 19.1% rise in short interest in January, totaling 25,600 shares. 首席执行官Mark T. Iwicki出售股票,而主要投资者Bros,顾问Lp Baker购买了大股权。 CEO Mark T. Iwicki sold shares, while major investor Bros. Advisors Lp Baker bought a large stake. 尽管Q3每股损失193美元,但该公司打破了分析师的预期,HC Wainwright保持了“购买”评级,价格目标为15.00美元。 Despite a Q3 loss of $1.93 per share, the company beat analyst expectations and HC Wainwright maintained a "buy" rating with a $15.00 price target.